Edition:
United States

Sanofi SA (SNY.N)

SNY.N on New York Stock Exchange

42.63USD
29 Jul 2016
Change (% chg)

$0.03 (+0.07%)
Prev Close
$42.60
Open
$41.64
Day's High
$42.74
Day's Low
$41.64
Volume
314,539
Avg. Vol
247,153
52-wk High
$54.98
52-wk Low
$37.41

SNY.N

Chart for SNY.N

About

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $108,691.40
Shares Outstanding(Mil.): 2,577.82
Dividend: 1.66
Yield (%): 3.90

Financials

  SNY.N Industry Sector
P/E (TTM): 22.60 38.77 39.28
EPS (TTM): 1.89 -- --
ROI: -- 15.17 14.40
ROE: -- 16.12 15.47

BRIEF-Sanofi, Pfizer, Gilead & Celgene interested in Medivation - CNBC citing sources

* Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - CNBC citing sources Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jul 29 2016

Sanofi sales and profit slide on U.S. pricing, Venezuela

PARIS French drugmaker Sanofi's sales and profit fell in the second quarter despite double-digit growth at biotech arm Genzyme, as the diabetes division came under sustained pricing pressure in the United States.

Jul 29 2016

UPDATE 1-Sanofi sales and profit slide on U.S. pricing, Venezuela

PARIS, July 29 French drugmaker Sanofi's sales and profit fell in the second quarter despite double-digit growth at biotech arm Genzyme, as the diabetes division came under sustained pricing pressure in the United States.

Jul 29 2016

French and Benelux stocks-Factors to watch on July 29

PARIS, July 29 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

Jul 29 2016

BRIEF-Zealand Pharma: royalty revenue of DKK 6.4 mln in Q2 on sales of Lyxumia

* Lixisenatide as adlyxin to treat type 2 diabetes commercial launch by Sanofi in U.S. is expected later in H2

Jul 29 2016

Sanofi sales and profit slide on U.S. pricing, Venezuela

PARIS, July 29 French drugmaker Sanofi's sales and profit fell in the second quarter despite double-digit growth at biotech arm Genzyme, as the diabetes division continued to come under sustained U.S. pricing pressure.

Jul 29 2016

BRIEF-Sanofi pasteur ships seasonal influenza vaccine doses in U.S.

* Ships First Of Its 2016 2017 seasonal influenza vaccine doses in United States

Jul 26 2016

BRIEF-Sanofi Enzyme says Ontario adds LEMTRADA to exceptional access program for eligible patients

* Ontario adds Lemtrada (Alemtuzumab) to exceptional access program for eligible patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 21 2016

Sanofi offers EU concessions over Boehringer consumer healthcare deal

BRUSSELS - French drugmaker Sanofi has sought to address EU antitrust concerns over its proposed takeover of German peer Boehringer Ingelheim's consumer health unit by offering concessions.

Jul 18 2016

Sanofi offers EU concessions over Boehringer consumer healthcare deal

BRUSSELS, July 18 - French drugmaker Sanofi has sought to address EU antitrust concerns over its proposed takeover of German peer Boehringer Ingelheim's consumer health unit by offering concessions.

Jul 18 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : New Constructs, LLC
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.